Table 3.

Response to Treatment Over Period of Follow-up

	Subjects, No. (%)
Follow-up Period and Outcome	Meglumine Antimoniate (n = 58)	Miltefosine (n = 58)
End of treatmenta
Apparent cure	17 (29.8)	27 (47.4)
Improvement	39 (68.4)	30 (52.6)
Early failure	1 (1.8)	0 (0)
Withdrawal without completion of treatment	1 (1.8)	1 (1.8)
Total	58	58
Week 13
Initial therapeutic response	41 (70.6)	53 (91.3)
Therapeutic failure at week 13	10 (17.2)	4 (6.9)
Unavailable for follow-up	1 (1.8)	0
Early failure	1 (1.8)	0
Did not attend week 13 visit	4 (6.9)	0
Withdrawal without completion of treatment	1 (1.8)	1 (1.8)
Total	58	58
Week 26
Final therapeutic response	40 (68.9)	48 (82.8)
Therapeutic failure at week 26	5 (8.6)	3 (5.2)
Early failure	1 (1.8)	0
Failure at week 13	10 (17.2)	4 (6.9)
Unavailable for follow-up	1 (1.8)	2 (3.4)
Withdrawal without completion of treatment	1 (1.8)	1 (1.8)
Total	58	58
Case closure
Cure	40 (69.0)	48 (82.8)
Failure	18 (31.0)	10 (17.2)
Total	58	58

^aThe treatment period was 20 days for meglumine antimoniate and 28 days for miltefosine.